Molecular progression of head and neck squamous cell carcinoma

被引:0
|
作者
Saha S.K. [1 ]
Maiti G.P. [1 ]
Roychoudhury S. [2 ]
Panda C.K. [1 ]
机构
[1] Chittaranjan National Cancer Institute (CNCI), 37 S. P. Mukherjee Road, Kolkata
[2] Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata
关键词
Candidate genes; Copy number variation; Cytogenetic abnormalities; HNSCC; HNSCC progression model; Molecular pathways;
D O I
10.1007/s13237-017-0212-9
中图分类号
学科分类号
摘要
Head and neck squamous cell carcinoma (HNSCC) is the most common and fatal cancer type in India with about 30–40% of frequency. Molecular etiologies of the disease include consumption of alcohol, tobacco habit and HPV infection. The lack of understanding in molecular pathogenesis of the disease leads to poor survival of HNSCC patients. Cytogenetic analysis has shown that the chromosomal abnormalities gradually increase with progression of the tumor in a non-random manner. Molecular analysis of- copy number variation, promoter methylation, mutation and expression (gene and protein) revealed identification of some of the candidate tumor suppressor genes located in the chromosomal 3p, 8q, 9p/q, 11q, 13q and 17p etc. regions associated with development of HNSCC. These genes are further seen to control different cellular pathways like- (1) frequent inactivation of SH3GL2 and CDC25A- associated with EGFR homeostasis and de-phosphorylation respectively; (2) Rb and p53 associated pathways in G1-S cell cycle transition; (3) Slit—ROBO associated signaling pathways; (4) PTCH associated Hedgehog signaling; (5) DNA repair pathways like- mismatch and double strand break repair; (6) apoptosis and (7) integrin signaling. Now, systemic approach has been taken to characterize the molecular pathways in this tumor to find out the key regulatory steps for management of the disease. © 2017, Archana Sharma Foundation of Calcutta.
引用
收藏
页码:111 / 119
页数:8
相关论文
共 50 条
  • [41] Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma
    Kordbacheh, Farzaneh
    Farah, Camile S.
    [J]. CANCERS, 2021, 13 (14)
  • [42] AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
    Brand, Toni M.
    Iida, Mari
    Stein, Andrew P.
    Corrigan, Kelsey L.
    Braverman, Cara M.
    Coan, John P.
    Pearson, Hannah E.
    Bahrar, Harsh
    Fowler, Tyler L.
    Bednarz, Bryan P.
    Saha, Sandeep
    Yang, David
    Gill, Parkash S.
    Lingen, Mark W.
    Saloura, Vassiliki
    Villaflor, Victoria M.
    Salgia, Ravi
    Kimple, Randall J.
    Wheeler, Deric L.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2601 - 2612
  • [43] Head and Neck Squamous Cell Carcinoma: Prognosis using molecular approach
    Mazumder, Tarikul Huda
    Nath, Sayantan
    Nath, Nibendu
    Kumar, Munish
    [J]. CENTRAL EUROPEAN JOURNAL OF BIOLOGY, 2014, 9 (06): : 593 - 613
  • [44] Molecular assay to detect metastatic head and neck squamous cell carcinoma
    Becker, MT
    Shores, CG
    Yu, KK
    Yarbrough, WG
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2004, 130 (01) : 21 - 27
  • [45] Hybrid conventional and sarcomatoid squamous carcinoma of head and neck: Molecular evidence for monoclonality and progression
    Zhai, Q
    Choi, HR
    Sturgis, E
    Luna, MA
    Batsakis, JG
    El-Naggar, AK
    [J]. LABORATORY INVESTIGATION, 2003, 83 (01) : 223A - 223A
  • [46] Hybrid conventional and sarcomatoid squamous carcinoma of head and neck: Molecular evidence for monoclonality and progression
    Zhai, Q
    Choi, HR
    Sturgis, E
    Luna, MA
    Batsakis, JG
    El-Naggar, AK
    [J]. MODERN PATHOLOGY, 2003, 16 (01) : 223A - 223A
  • [47] Biomarkers of squamous cell carcinoma of the head and neck
    Kim, J
    Shin, DM
    [J]. HISTOLOGY AND HISTOPATHOLOGY, 1997, 12 (01) : 205 - 218
  • [48] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Moskovitz, Jessica
    Moy, Jennifer
    Ferris, Robert L.
    [J]. CURRENT ONCOLOGY REPORTS, 2018, 20 (02)
  • [49] Afatinib in squamous cell carcinoma of the head and neck
    Specenier, Pol
    Vermorken, Jan
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1295 - 1301